Cerus Corp (CERS) 6.36 $CERS
Cerus to Present at the Baird 2016 Healthcare Conference on September 8, 2016
BusinessWire - Thu Sep 01, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that Kevin Green, Cerus' vice president, finance and chief financial officer, is scheduled to present a corporate update at the Baird 2016 Healthcare Conference at 12:50PM ET on Thursday, September 8, 2016.
CERS: 6.36 (unch)
Noteworthy Wednesday Option Activity: CERS, LGF, X
DividendChannel.com - Wed Aug 31, 2:29PM CDT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cerus Corp. , where a total of 13,934 contracts have traded so far, representing approximately 1.4 million underlying shares.
CERS: 6.36 (unch)
SmarTrend Watching for Potential Pullback in Shares of Cerus After 1.78% Gain
Comtex SmarTrend(R) - Mon Aug 29, 4:39PM CDT
Cerus (NASDAQ:CERS) traded in a range yesterday that spanned from a low of $6.83 to a high of $7.19. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $6.89 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CERS: 6.36 (unch)
FDA's New Recommendation for Universal Zika Risk Reduction of Blood Components Includes Use of Pathogen Reduction
BusinessWire - Mon Aug 29, 7:30AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that the U.S. Food and Drug Administration (FDA) has issued a revised guidance document, titled "Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components," which extends its recommendation of appropriate blood safety measures to apply to all U.S. blood centers. Use of pathogen reduction, such as the INTERCEPT Blood System for platelets and plasma, is specified as an acceptable safety measure.
CERS: 6.36 (unch)
Vivek Jayaraman Appointed as Cerus Corporation's Chief Commercial Officer
BusinessWire - Tue Aug 09, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today the appointment of Vivek Jayaraman as chief commercial officer, effective August 29th, 2016. Mr. Jayaraman joins Cerus from TriVascular Technologies, Inc. where he previously served as vice president of sales and marketing.
CERS: 6.36 (unch), TRIV: 5.87 (+0.42), ELGX: 12.22 (unch)
Cerus Corporation Reports Second Quarter 2016 Results
BusinessWire - Thu Aug 04, 3:01PM CDT
Cerus Corporation (NASDAQ:CERS) today announced financial results for the second quarter ended June 30, 2016.
CERS: 6.36 (unch)
Research Report Initiation on These Biotech Stocks -- Tesaro, Cerus, Five Prime Therapeutics, and Intercept Pharma
PR Newswire - Thu Aug 04, 7:20AM CDT
The Biotech industry has been showing signs of strength in the previous days due to increased M&A activities and lesser regulatory and political pressures. On Tuesday, the iShares NASDAQ Biotechnology ETF rose to a high of $299 per share, as per CNBC. Stock-Callers.com takes a look at the following equities and see if they are poised for growth: Tesaro Inc. (NASDAQ: TSRO), Cerus Corp. (NASDAQ: CERS), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Learn more about these stocks by downloading their free report at:
CERS: 6.36 (unch), TSRO: 84.87 (+0.52), ICPT: 150.74 (+3.92), FPRX: 43.71 (-1.03)
22.9% Return Seen to Date on SmarTrend Cerus Call (CERS)
Comtex SmarTrend(R) - Tue Aug 02, 1:05AM CDT
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on June 7th, 2016 at $5.95. In approximately 2 months, Cerus has returned 22.86% as of today's recent price of $7.31.
CERS: 6.36 (unch)
Cerus (CERS) in Focus: Stock Moves 6% Higher in Session
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:05AM CDT
Cerus Corporation (CERS) was a big mover last session, as the company saw its shares rise a little over 6% on the day.
CERS: 6.36 (unch), LMAT: 18.35 (+0.59)
Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program
BusinessWire - Sun Jun 19, 3:00PM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, to support Cerus' clinical development program for pathogen reduction of red blood cell (RBC) components, including access to funding that could support various activities, including funding studies necessary to support an FDA submission and accelerate commercial scale up to facilitate potential adoption by U.S. blood centers.
CERS: 6.36 (unch)
Showpad Helps Cerus Corporation Share Vital Information During Zika Epidemic
PR Newswire Europe - Wed Jun 01, 1:30AM CDT
Showpad, the leading sales enablement platform that guides reps to results, today announced that its customer Cerus Corporation, a biomedical company focused in the field of blood transfusion safety, is using Showpad to help educate its blood center customers about ways to maintain the safety of the blood supply during a Zika epidemic. Cerus is able to leverage the Showpad platform quickly and efficiently to share vital medical information with its field sales organization.
CERS: 6.36 (unch)
How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.36 (unch), RDUS: 56.56 (+0.88), ARWR: 7.15 (+0.09), FPRX: 43.71 (-1.03)
Health Canada Approves INTERCEPT Blood System for Plasma
BusinessWire - Mon May 23, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) today announced that Health Canada has approved the INTERCEPT Blood System for plasma. The INTERCEPT Blood System for plasma is intended to be used for the ex vivo preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 6.36 (unch)
Cerus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Tuesday reported a loss of $16.9 million in its first quarter.
CERS: 6.36 (unch)
Cerus Corporation Reports First Quarter 2016 Results
BusinessWire - Tue May 03, 3:01PM CDT
Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2016.
CERS: 6.36 (unch)
Cerus Announces that the Walter Reed National Military Medical Center Has Entered Into Routine Use of the INTERCEPT Blood System
BusinessWire - Tue May 03, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS), a biomedical products company focused in the field of blood transfusion safety, announced today that the Walter Reed National Military Medical Center (Walter Reed), a component of the Armed Services Blood Program, has begun routine use of the INTERCEPT Blood System for apheresis platelets. Walter Reed transfuses approximately 1,000 apheresis platelet units annually.
CERS: 6.36 (unch)
Cerus to Release First Quarter 2016 Results on May 3, 2016
BusinessWire - Tue Apr 19, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Tuesday, May 3, 2016, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 6.36 (unch)
The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 16, 1:18PM CDT
The Aedes aegypti mosquito has become public enemy No. 1. Image source: Centers for Disease Control and Prevention. The Zika virus has been around for decades, but its prevalence has exploded since 2014. The virus itself, which is spread by the...
CERS: 6.36 (unch), INO: 9.08 (-0.06), MRK: 62.98 (+0.08), NLNK: 9.91 (-0.40), XON: 25.33 (+0.04), GSK: 44.26 (+1.28), SNY: 39.18 (+0.77)
Covered Call Alerts For Bank of America, CERUS Corporation, Seadrill, Johnson & Johnson and Facebook Released By InvestorsObserver
PR Newswire - Wed Feb 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for BAC, CERS, SDRL, JNJ and FB.
CERS: 6.36 (unch), JNJ: 119.32 (+0.24), FB: 126.51 (+0.34), BAC: 16.00 (+0.02), SDRL: 2.42 (+0.09)
Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma
BusinessWire - Tue Feb 09, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that the American Red Cross has signed a multi-year purchase agreement for the INTERCEPT Blood System for platelets and plasma, which inactivates a broad spectrum of viruses, gram-positive and gram-negative bacteria, spirochetes, parasites and leukocytes and is intended to reduce the risk of transfusion-transmitted infection (TTI) in platelet and plasma components.
CERS: 6.36 (unch)
Cerus to Present at the Baird 2016 Healthcare Conference on September 8, 2016
BusinessWire - Thu Sep 01, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that Kevin Green, Cerus' vice president, finance and chief financial officer, is scheduled to present a corporate update at the Baird 2016 Healthcare Conference at 12:50PM ET on Thursday, September 8, 2016.
CERS: 6.36 (unch)
Noteworthy Wednesday Option Activity: CERS, LGF, X
DividendChannel.com - Wed Aug 31, 2:29PM CDT
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Cerus Corp. , where a total of 13,934 contracts have traded so far, representing approximately 1.4 million underlying shares.
CERS: 6.36 (unch)
SmarTrend Watching for Potential Pullback in Shares of Cerus After 1.78% Gain
Comtex SmarTrend(R) - Mon Aug 29, 4:39PM CDT
Cerus (NASDAQ:CERS) traded in a range yesterday that spanned from a low of $6.83 to a high of $7.19. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $6.89 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CERS: 6.36 (unch)
FDA's New Recommendation for Universal Zika Risk Reduction of Blood Components Includes Use of Pathogen Reduction
BusinessWire - Mon Aug 29, 7:30AM CDT
Cerus Corporation (NASDAQ: CERS) announced today that the U.S. Food and Drug Administration (FDA) has issued a revised guidance document, titled "Revised Recommendations for Reducing the Risk of Zika Virus Transmission by Blood and Blood Components," which extends its recommendation of appropriate blood safety measures to apply to all U.S. blood centers. Use of pathogen reduction, such as the INTERCEPT Blood System for platelets and plasma, is specified as an acceptable safety measure.
CERS: 6.36 (unch)
Vivek Jayaraman Appointed as Cerus Corporation's Chief Commercial Officer
BusinessWire - Tue Aug 09, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today the appointment of Vivek Jayaraman as chief commercial officer, effective August 29th, 2016. Mr. Jayaraman joins Cerus from TriVascular Technologies, Inc. where he previously served as vice president of sales and marketing.
CERS: 6.36 (unch), TRIV: 5.87 (+0.42), ELGX: 12.22 (unch)
Cerus Corporation Reports Second Quarter 2016 Results
BusinessWire - Thu Aug 04, 3:01PM CDT
Cerus Corporation (NASDAQ:CERS) today announced financial results for the second quarter ended June 30, 2016.
CERS: 6.36 (unch)
Research Report Initiation on These Biotech Stocks -- Tesaro, Cerus, Five Prime Therapeutics, and Intercept Pharma
PR Newswire - Thu Aug 04, 7:20AM CDT
The Biotech industry has been showing signs of strength in the previous days due to increased M&A activities and lesser regulatory and political pressures. On Tuesday, the iShares NASDAQ Biotechnology ETF rose to a high of $299 per share, as per CNBC. Stock-Callers.com takes a look at the following equities and see if they are poised for growth: Tesaro Inc. (NASDAQ: TSRO), Cerus Corp. (NASDAQ: CERS), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Learn more about these stocks by downloading their free report at:
CERS: 6.36 (unch), TSRO: 84.87 (+0.52), ICPT: 150.74 (+3.92), FPRX: 43.71 (-1.03)
22.9% Return Seen to Date on SmarTrend Cerus Call (CERS)
Comtex SmarTrend(R) - Tue Aug 02, 1:05AM CDT
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on June 7th, 2016 at $5.95. In approximately 2 months, Cerus has returned 22.86% as of today's recent price of $7.31.
CERS: 6.36 (unch)
Cerus (CERS) in Focus: Stock Moves 6% Higher in Session
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:05AM CDT
Cerus Corporation (CERS) was a big mover last session, as the company saw its shares rise a little over 6% on the day.
CERS: 6.36 (unch), LMAT: 18.35 (+0.59)
Cerus Announces Agreement with BARDA for Potential Funding of up to Approximately $180 Million to Advance Its INTERCEPT Red Blood Cell Program
BusinessWire - Sun Jun 19, 3:00PM CDT
Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on improving blood transfusion safety, today announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, to support Cerus' clinical development program for pathogen reduction of red blood cell (RBC) components, including access to funding that could support various activities, including funding studies necessary to support an FDA submission and accelerate commercial scale up to facilitate potential adoption by U.S. blood centers.
CERS: 6.36 (unch)
Showpad Helps Cerus Corporation Share Vital Information During Zika Epidemic
PR Newswire Europe - Wed Jun 01, 1:30AM CDT
Showpad, the leading sales enablement platform that guides reps to results, today announced that its customer Cerus Corporation, a biomedical company focused in the field of blood transfusion safety, is using Showpad to help educate its blood center customers about ways to maintain the safety of the blood supply during a Zika epidemic. Cerus is able to leverage the Showpad platform quickly and efficiently to share vital medical information with its field sales organization.
CERS: 6.36 (unch)
How Well are These Healthcare Stocks Performing? - Radius Health, Cerus, Arrowhead Pharma, and Five Prime Therapeutics
PR Newswire - Thu May 26, 7:50AM CDT
Despite the volatility that continues to envelop the Biotech industry, investors see value in this space. Today's pre-market research on ActiveWallSt.com directs the investor community's focus on the following Healthcare equities: Radius Health Inc. (NASDAQ: RDUS), Cerus Corp. (NASDAQ: CERS), Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), and Five Prime Therapeutics Inc. (NASDAQ: FPRX). Register with us today for these stock technical briefings at:
CERS: 6.36 (unch), RDUS: 56.56 (+0.88), ARWR: 7.15 (+0.09), FPRX: 43.71 (-1.03)
Health Canada Approves INTERCEPT Blood System for Plasma
BusinessWire - Mon May 23, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) today announced that Health Canada has approved the INTERCEPT Blood System for plasma. The INTERCEPT Blood System for plasma is intended to be used for the ex vivo preparation of pathogen-reduced, whole blood derived or apheresis plasma in order to reduce the risk of transfusion-transmitted infection (TTI).
CERS: 6.36 (unch)
Cerus reports 1Q loss
Automated Insights - Tue May 03, 3:37PM CDT
CONCORD, Calif. (AP) _ Cerus Corp. (CERS) on Tuesday reported a loss of $16.9 million in its first quarter.
CERS: 6.36 (unch)
Cerus Corporation Reports First Quarter 2016 Results
BusinessWire - Tue May 03, 3:01PM CDT
Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2016.
CERS: 6.36 (unch)
Cerus Announces that the Walter Reed National Military Medical Center Has Entered Into Routine Use of the INTERCEPT Blood System
BusinessWire - Tue May 03, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS), a biomedical products company focused in the field of blood transfusion safety, announced today that the Walter Reed National Military Medical Center (Walter Reed), a component of the Armed Services Blood Program, has begun routine use of the INTERCEPT Blood System for apheresis platelets. Walter Reed transfuses approximately 1,000 apheresis platelet units annually.
CERS: 6.36 (unch)
Cerus to Release First Quarter 2016 Results on May 3, 2016
BusinessWire - Tue Apr 19, 7:30AM CDT
Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results will be released on Tuesday, May 3, 2016, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.
CERS: 6.36 (unch)
The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 16, 1:18PM CDT
The Aedes aegypti mosquito has become public enemy No. 1. Image source: Centers for Disease Control and Prevention. The Zika virus has been around for decades, but its prevalence has exploded since 2014. The virus itself, which is spread by the...
CERS: 6.36 (unch), INO: 9.08 (-0.06), MRK: 62.98 (+0.08), NLNK: 9.91 (-0.40), XON: 25.33 (+0.04), GSK: 44.26 (+1.28), SNY: 39.18 (+0.77)
Covered Call Alerts For Bank of America, CERUS Corporation, Seadrill, Johnson & Johnson and Facebook Released By InvestorsObserver
PR Newswire - Wed Feb 10, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for BAC, CERS, SDRL, JNJ and FB.
CERS: 6.36 (unch), JNJ: 119.32 (+0.24), FB: 126.51 (+0.34), BAC: 16.00 (+0.02), SDRL: 2.42 (+0.09)
Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma
BusinessWire - Tue Feb 09, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that the American Red Cross has signed a multi-year purchase agreement for the INTERCEPT Blood System for platelets and plasma, which inactivates a broad spectrum of viruses, gram-positive and gram-negative bacteria, spirochetes, parasites and leukocytes and is intended to reduce the risk of transfusion-transmitted infection (TTI) in platelet and plasma components.
CERS: 6.36 (unch)
